Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women

Background: Controlled pharmacokinetic (PK) studies in United States populations have defined categories of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) for various pre-exposure prophylaxis (PrEP) adherence targets. It is unknown how these categories perform in other populations. Theref...

Full description

Bibliographic Details
Main Authors:	Maria Pyra, Pete Anderson, Jessica E. Haberer, Renee Heffron, Connie Celum, Stephen Asiimwe, Elly Katabira, Nelly R. Mugo, Elizabeth A. Bukusi, Jared M. Baeten
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-04-01
Series:	Frontiers in Pharmacology
Subjects:	tenofovir-diphosphate adherence pre-exposure prophylaxis women Africa HIV
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.00401/full

Similar Items

Perceptions of pregnancy occurring among HIV-serodiscordant couples in Kenya
by: Grace Kimemia, et al.
Published: (2019-06-01)

Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the “PrEP as a bridge to ART” strategy
by: Nicholas Musinguzi, et al.
Published: (2020-10-01)

The Incremental Cost of Delivering PrEP as a Bridge to ART for HIV Serodiscordant Couples in Public HIV Care Clinics in Kenya
by: Elizabeth M. Irungu, et al.
Published: (2019-01-01)

Dynamic Perceived HIV Risk and Sexual Behaviors Among Young Women Enrolled in a PrEP Trial in Kenya: A Qualitative Study
by: Kenneth Ngure, et al.
Published: (2021-08-01)

Psychosocial Experiences of Adolescent Girls and Young Women Subsequent to an Abortion in Sub-saharan Africa and Globally: A Systematic Review
by: Yasaman Zia, et al.
Published: (2021-05-01)

Contraception and sexually transmitted infections: risks and benefits, hypotheses and evidence
by: Jared M Baeten, et al.
Published: (2015-08-01)

A Scoring Tool to Identify East African HIV-1 Serodiscordant Partnerships with a High Likelihood of Pregnancy.
by: Renee Heffron, et al.
Published: (2015-01-01)

Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships
by: Asiimwe, S., et al.
Published: (2018)

Circumcision of male children for reduction of future risk for HIV: acceptability among HIV serodiscordant couples in Kampala, Uganda.
by: Kenneth K Mugwanya, et al.
Published: (2011-01-01)

Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda.
by: Timothy R Muwonge, et al.
Published: (2020-01-01)

Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
by: Baeten Jared M, et al.
Published: (2011-03-01)

The role of male partners in women’s participation in research during pregnancy: a case study from the partners demonstration project
by: Kenneth Ngure, et al.
Published: (2017-12-01)

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
by: Jared M Baeten, et al.
Published: (2016-08-01)

Health Care Providers as Agents of Change: Integrating PrEP With Other Sexual and Reproductive Health Services for Adolescent Girls and Young Women
by: Gabrielle O'Malley, et al.
Published: (2021-05-01)

Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions.
by: Patrick Ndase, et al.
Published: (2015-01-01)

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
by: Tim R. Cressey, et al.
Published: (2020-08-01)

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa [version 2; referees: 2 approved]
by: Renee Heffron, et al.
Published: (2018-01-01)

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa [version 1; referees: 2 approved]
by: Renee Heffron, et al.
Published: (2017-11-01)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
by: Tim R. Cressey, et al.
Published: (2017-07-01)

Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations
by: Ayokunle O. Olanrewaju, et al.
Published: (2021-04-01)

Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.
by: Craig R Cohen, et al.
Published: (2012-01-01)

The structure and mechanism of fructose diphosphate aldolase from yeast.
by: Wiebe, John
Published: (1973)

Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples
by: Jillian Pintye, MPH, et al.
Published: (2014-11-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial
by: de Bruyn Guy, et al.
Published: (2012-10-01)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
by: Linden Lalley-Chareczko, et al.
Published: (2020-03-01)

Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity
by: Rachel A. Murphy, et al.
Published: (2017-03-01)

Tenofovir-induced Leukocytoclastic Vasculitis
by: Said A. Al-Busafi, et al.
Published: (2017-09-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

An overview of tenofovir and renal disease for the HIV-treating clinician
by: Willem D.F. Venter, et al.
Published: (2018-07-01)

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.
by: Britta L Jewell, et al.
Published: (2015-01-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Tenofovir-associated kidney disease in Africans: a systematic review
by: Takudzwa J. Mtisi, et al.
Published: (2019-06-01)

Identification of a novel class of ω,E,E-farnesyl diphosphate synthase from Mycobacterium tuberculosis
by: Rakesh K. Dhiman, et al.
Published: (2004-06-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

PrEP as a Lifestyle and Investment for Adolescent Girls and Young Women in Sub-Saharan Africa
by: Jessica E. Haberer MD, MS, et al.
Published: (2019-02-01)

Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
by: Kenneth K Mugwanya, et al.
Published: (2016-09-01)